Sign In
Buy ALNY
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
07:38am, Thursday, 09'th Jul 2026
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
12:56pm, Monday, 06'th Jul 2026
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
06:33am, Thursday, 02'nd Jul 2026
The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has a unique drug delivery system that gives it a deeper moat.
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
05:12pm, Thursday, 25'th Jun 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
09:00am, Thursday, 25'th Jun 2026
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasd
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
09:31am, Monday, 22'nd Jun 2026
Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term
10:51am, Tuesday, 16'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
10:21am, Friday, 12'th Jun 2026
Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
09:00am, Friday, 12'th Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” w
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
07:47am, Wednesday, 10'th Jun 2026
ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
08:22pm, Tuesday, 09'th Jun 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts
01:04pm, Tuesday, 09'th Jun 2026
Alnylam Pharmaceuticals NASDAQ: ALNY executives outlined the company's 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst S
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500
05:06pm, Monday, 08'th Jun 2026
The index added two companies on Friday, but more are likely to be added in the near future.
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
12:31pm, Thursday, 04'th Jun 2026
ALNY teams up with Inceptive in a deal worth up to $2B, using AI models and proprietary RNAi data to speed drug discovery and improve candidate selection.
